Neupro (Rotigotine) Transdermal Patch
Dopamine agonist patch for Restless Legs Syndrome (RLS)
Quick Facts About Neupro
Key Takeaways About Neupro
- Continuous 24-hour delivery: The transdermal patch provides steady dopaminergic stimulation throughout the day, which may reduce symptom fluctuations compared to oral medications
- Must remove before MRI: The patch contains aluminium and must be removed before any MRI scan or cardioversion to prevent skin burns
- Watch for impulse control issues: Like all dopamine agonists, Neupro can cause pathological gambling, compulsive shopping, binge eating, or hypersexuality
- Never stop suddenly: Abrupt discontinuation can trigger neuroleptic malignant syndrome (NMS), a potentially life-threatening condition
- Rotate application site: Apply the patch to a different area each day and do not reuse the same skin site within 14 days to avoid irritation
What Is Neupro and What Is It Used For?
Neupro (rotigotine) is a transdermal patch containing a dopamine agonist used to treat Restless Legs Syndrome (RLS) in adults. It works by stimulating dopamine receptors in the brain, reducing the uncomfortable sensations and involuntary urge to move the legs that characterise RLS.
Rotigotine, the active ingredient in Neupro, belongs to a class of medications called dopamine agonists. Dopamine is a chemical messenger (neurotransmitter) in the brain that plays a critical role in controlling movement, motivation, and the reward system. In conditions like Restless Legs Syndrome, dopaminergic pathways are thought to be dysfunctional, leading to the hallmark symptoms of the disorder.
Unlike oral dopamine agonists such as pramipexole or ropinirole, Neupro is delivered through the skin via a transdermal patch. This method of administration provides continuous, steady-state drug delivery over a full 24-hour period. The continuous delivery is clinically significant because it avoids the peaks and troughs in blood levels that occur with oral dosing, potentially reducing side effects while maintaining therapeutic efficacy around the clock.
Neupro is specifically approved for the treatment of moderate-to-severe Restless Legs Syndrome in adults. RLS affects approximately 5–10% of the general population and is characterised by an irresistible urge to move the legs, typically accompanied by unpleasant crawling, tingling, or aching sensations. Symptoms are usually worse during periods of inactivity (such as sitting or lying down) and tend to worsen in the evening and at night, frequently leading to significant sleep disruption and reduced quality of life.
Rotigotine is a non-ergoline dopamine agonist that activates dopamine receptor subtypes D1 through D5, with preferential activity at the D3 receptor. The D3 receptor is particularly relevant in the pathophysiology of RLS, as it is concentrated in the limbic system and areas of the brain involved in sensory processing and movement regulation. By stimulating these receptors, rotigotine helps to restore normal dopaminergic signalling and alleviate the motor and sensory symptoms of RLS.
The Neupro patch is designed to release a precise amount of rotigotine through the skin into the bloodstream continuously over 24 hours. Because the drug bypasses the gastrointestinal tract and first-pass liver metabolism, food and drink do not affect its absorption. This makes it a convenient option for patients who have difficulty swallowing tablets or who experience gastrointestinal side effects with oral dopamine agonists.
What Should You Know Before Using Neupro?
Before using Neupro, it is essential to inform your doctor about all medical conditions, especially liver problems, cardiovascular disease, and any history of mental health disorders. The patch must never be worn during MRI scans or cardioversion due to its aluminium content.
Contraindications
Neupro must not be used in certain situations where the risks clearly outweigh any potential benefits. You should not use Neupro if:
- Allergy to rotigotine: If you are allergic to rotigotine or any of the other ingredients in the patch (including sodium metabisulfite E223), you must not use Neupro
- MRI procedures: The patch must be removed before undergoing magnetic resonance imaging (MRI) because it contains aluminium backing that can heat up during the scan and cause skin burns
- Cardioversion: Similarly, the patch must be removed before electrical cardioversion (a procedure used to treat abnormal heart rhythms) due to the same risk of burns from the metallic components
After removing the patch for an MRI scan or cardioversion, you may apply a new patch once the procedure is complete. However, always consult with the healthcare team performing the procedure about the appropriate timing.
Warnings and Precautions
Several important precautions should be discussed with your doctor before starting Neupro. These include monitoring requirements and potential risks that require careful clinical management.
Blood pressure monitoring: Neupro can affect blood pressure, particularly when treatment is first started or the dose is increased. Your blood pressure should be checked regularly, especially during the initial weeks of therapy. Orthostatic hypotension (a sudden drop in blood pressure upon standing) is a known effect that can cause dizziness, lightheadedness, or fainting.
Eye examinations: Regular eye check-ups are recommended during treatment with Neupro. If you notice any changes in your vision between scheduled examinations, contact your doctor immediately.
Liver function: If you have significant liver impairment, your doctor may need to adjust your dose. Report any worsening of liver problems during treatment to your doctor promptly, as dose modifications or discontinuation may be necessary.
Sudden sleep onset: Neupro can cause excessive drowsiness and sudden episodes of falling asleep without warning. In rare cases, patients have fallen asleep while driving or operating machinery, leading to accidents. If you experience excessive sleepiness, do not drive or engage in activities requiring alertness until the issue is resolved with your doctor.
Augmentation: In patients with RLS, a phenomenon called augmentation can occur where symptoms begin earlier in the day, become more intense, or spread to involve other body parts (such as the arms). If you experience any of these changes, contact your doctor as treatment adjustments may be necessary.
Neupro can cause syncope (loss of consciousness), particularly when treatment is first started or when the dose is increased. If you experience fainting episodes or feel faint, inform your doctor immediately. This may require dose adjustment or additional monitoring.
Impulse Control Disorders
One of the most clinically significant adverse effects associated with dopamine agonists, including Neupro, is the development of impulse control disorders (ICDs). These are behavioural changes that patients may not recognise in themselves, making it vital that family members and caregivers are informed about these potential effects.
Impulse control disorders associated with Neupro can include:
- Pathological gambling: A strong compulsion to gamble despite serious financial or personal consequences
- Hypersexuality: Significantly increased sexual desire or behaviour that causes distress to the patient or others
- Compulsive spending: An uncontrollable urge to buy things or spend money excessively
- Binge eating: Consuming large amounts of food in short periods, or eating significantly more than needed
- Dopamine dysregulation syndrome: A craving for increasingly higher doses of the medication beyond what is clinically needed
If you or your caregiver notice any of these behaviours, consult your doctor immediately. These effects are typically dose-dependent and may resolve with dose reduction or discontinuation of the medication.
Pregnancy and Breastfeeding
Neupro should not be used during pregnancy, as the effects of rotigotine on the developing foetus are not well established. Women of childbearing potential should discuss effective contraception with their doctor before starting treatment.
Breastfeeding is not recommended during treatment with Neupro. Rotigotine may pass into breast milk and could potentially affect the nursing infant. Additionally, rotigotine may suppress prolactin production, which can reduce milk supply. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, consult your doctor before using this medication.
Children and Adolescents
Neupro is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of rotigotine in this population have not been established, and there is insufficient data to support its use in paediatric patients.
How Does Neupro Interact with Other Drugs?
Neupro can interact with several classes of medications, including antipsychotics, anti-emetics, sedatives, and blood pressure-lowering drugs. Some interactions can reduce Neupro's effectiveness, while others can amplify its side effects. Always inform your doctor about all medications you are taking.
Drug interactions are an important consideration when using Neupro. Because rotigotine acts on dopamine receptors, medications that block or enhance dopaminergic activity can significantly affect its therapeutic profile. Understanding these interactions helps ensure safe and effective use of the medication.
| Interacting Drug | Type | Effect | Recommendation |
|---|---|---|---|
| Antipsychotics (e.g., haloperidol, olanzapine) | Major | Block dopamine receptors, directly counteracting rotigotine's mechanism of action | Avoid combination; discuss alternatives with your doctor |
| Metoclopramide | Major | Dopamine antagonist that reduces Neupro effectiveness | Avoid combination; use alternative anti-emetics |
| Benzodiazepines (e.g., diazepam, lorazepam) | Moderate | Additive sedation; increased risk of drowsiness and sudden sleep episodes | Use with caution; monitor for excessive sedation |
| Antidepressants (sedating types) | Moderate | Enhanced CNS depression; increased drowsiness | Use with caution; dose adjustment may be needed |
| Antihypertensive drugs | Moderate | Additive blood pressure lowering; increased risk of orthostatic hypotension | Monitor blood pressure closely, especially when standing |
| Alcohol | Moderate | Enhanced sedation and impaired cognitive function | Discuss alcohol use with your doctor; avoid or limit intake |
Since rotigotine is absorbed through the skin and enters the bloodstream directly, food and drink do not affect how the medication is absorbed. However, the concomitant use of alcohol with Neupro is discouraged because it may potentiate the sedative effects of the medication and increase the risk of sudden sleep onset.
Always inform your doctor or pharmacist about all medications you are taking, including over-the-counter drugs, herbal remedies, and supplements. This includes any medications you may have started or stopped recently. Some interactions may not become apparent immediately and require ongoing monitoring.
What Is the Correct Dosage of Neupro?
For Restless Legs Syndrome, Neupro treatment starts with 1 mg/24h and may be increased weekly by 1 mg/24h up to a maximum of 3 mg/24h. The patch is applied once daily and worn for 24 hours before being replaced with a new one on a different skin site.
Neupro dosing follows a careful titration protocol to minimise side effects while achieving optimal symptom control. The dose should always be individualised based on clinical response and tolerability. Never change your dose without consulting your doctor.
Adults with Restless Legs Syndrome
Starting Dose
One 1 mg/24h patch applied once daily. The patch should be worn continuously for 24 hours and then replaced with a new one.
Dose Titration
Starting from the second week, the daily dose may be increased by 1 mg per week until the optimal maintenance dose is reached. The target is the lowest dose that adequately controls symptoms with acceptable side effects.
Maximum Dose
3 mg/24h is the maximum recommended dose for RLS. Doses above this level have not shown additional benefit and are associated with increased side effects.
| Week | Daily Dose | Patch Strength | Notes |
|---|---|---|---|
| Week 1 | 1 mg/24h | 1 mg/24h patch | Starting dose; monitor for tolerability |
| Week 2 | 2 mg/24h | 2 mg/24h patch | Increase if needed and tolerated |
| Week 3 | 3 mg/24h | 3 mg/24h patch | Maximum dose for RLS |
How to Apply the Patch
Proper application of the Neupro patch is crucial for ensuring consistent drug delivery and minimising skin reactions. Follow these guidelines carefully:
- Choose a clean, dry skin site: Apply to the shoulders, upper arms, abdomen, flanks (sides between ribs and hips), thighs, or hips
- Remove the old patch first: Always take off the previous patch before applying a new one
- Open the pouch and peel the liner: Handle the patch carefully, avoiding touching the adhesive side with your fingers
- Press firmly for 30 seconds: Place the adhesive side on the skin and press with the palm of your hand to ensure good contact, especially around the edges
- Wash your hands: After handling the patch, wash your hands with soap and water immediately
Apply the patch to a different area of skin each day. For example, alternate between the right side one day and the left side the next, or between the upper and lower body. Do not reuse the same skin area within 14 days. If the application site is hairy, shave the area at least 3 days before applying the patch. Do not apply the patch to broken, irritated, or red skin.
Missed Dose
If you forget to change the patch at the usual time, remove the old patch and apply a new one as soon as you remember. If you forgot to apply a new patch after removing the old one, apply a new patch as soon as you remember. In both cases, apply the next patch at your usual time the following day. Do not use a double dose to make up for a forgotten one.
Overdose
Using higher doses of Neupro than prescribed can lead to serious adverse effects including nausea, vomiting, low blood pressure, hallucinations (seeing or hearing things that are not real), confusion, excessive drowsiness, involuntary movements (dyskinesia), and seizures. If you suspect an overdose, remove the patch immediately and contact your doctor or emergency services. They will advise you on appropriate supportive measures.
Sudden discontinuation of Neupro can cause neuroleptic malignant syndrome (NMS), a potentially life-threatening condition characterised by muscle rigidity, high fever, unstable blood pressure, rapid heart rate, confusion, and reduced consciousness. If your doctor decides to stop treatment, the dose should be reduced gradually – typically decreasing by 1 mg every other day for RLS patients.
What Are the Side Effects of Neupro?
Like all medicines, Neupro can cause side effects, though not everyone experiences them. The most common include headache, nausea, fatigue, and skin irritation at the application site. Serious but less common effects include sudden sleep onset, impulse control disorders, and hallucinations.
Side effects with Neupro are often most pronounced during the initial weeks of treatment or when the dose is increased. Nausea and skin reactions at the application site are particularly common early on but usually diminish as the body adjusts to the medication. Understanding the frequency and nature of potential side effects helps patients and their caregivers recognise when medical attention is needed.
Very Common
- Headache
- Nausea
- Fatigue and weakness
- Skin irritation at patch site (redness, itching)
Common
- Itching (pruritus)
- Irritability
- Allergic reactions
- Increased sexual drive
- High blood pressure
- Vomiting, heartburn
- Swelling in legs and feet (oedema)
- Drowsiness, sudden sleep episodes
- Difficulty sleeping, unusual dreams
- Impulse control disorders (gambling, compulsive shopping, binge eating)
Uncommon
- Restlessness (agitation)
- Orthostatic hypotension (dizziness on standing)
Rare and Very Rare
- Aggression, disorientation
- Hallucinations (visual and auditory)
- Paranoia, psychotic disorders, delusions, delirium
- Syncope (fainting), involuntary movements (dyskinesia)
- Seizures (convulsions)
- Blurred vision, visual disturbances
- Palpitations, abnormal heart rhythm
- Low blood pressure, hiccups
- Constipation, dry mouth, diarrhoea
- Rhabdomyolysis (severe muscle breakdown)
- Erectile dysfunction
- Dopamine dysregulation syndrome
Skin Reactions at the Application Site
Application site reactions are among the most commonly reported side effects with the Neupro patch. You may experience redness, itching, or mild irritation where the patch has been applied. These reactions are generally mild to moderate in severity and resolve within a few hours after patch removal.
To minimise the risk and severity of skin reactions:
- Rotate the application site daily, using a different area each time
- Do not apply a new patch to the same area within 14 days
- Apply only to clean, dry, intact skin free of lotions, oils, or powders
- Protect areas with skin reactions from direct sunlight, as this may cause skin discolouration
If skin reactions persist for more than a few days, are severe, or spread beyond the application site, contact your doctor for advice. In some cases, treatment modification or discontinuation may be necessary.
Allergic Reactions
Neupro contains sodium metabisulfite (E223), which can rarely cause severe hypersensitivity (allergic) reactions and bronchospasm (breathing difficulty caused by narrowing of the airways). Contact your doctor immediately if you experience swelling of the face, tongue, or lips, difficulty breathing, or a widespread rash.
How Should You Store Neupro?
Store Neupro patches at or below 30°C (86°F), in their original sachets, and out of the reach of children. Used patches still contain active medication and should be folded in half with the adhesive side inward and disposed of safely.
Proper storage of Neupro patches is important to ensure the medication remains effective and safe throughout its shelf life. Follow these guidelines:
- Temperature: Store at a temperature not exceeding 30°C (86°F). Do not freeze.
- Packaging: Keep each patch in its sealed sachet until you are ready to use it. Do not open the sachet in advance.
- Children: Keep all patches – both used and unused – out of the sight and reach of children.
- Expiry date: Do not use the patch after the expiry date printed on the label and carton.
Disposing of Used Patches
Used patches still contain significant amounts of active rotigotine and must be disposed of carefully to prevent accidental exposure. Fold the used patch in half with the adhesive side facing inward, place it back in its original sachet, and dispose of it safely out of the reach of children and pets.
Do not flush used patches down the toilet or throw them into household waste where they could be accessible. Ask your pharmacist about proper disposal methods for medications in your area. These precautions help protect the environment and prevent accidental exposure.
What Does Neupro Contain?
The active ingredient in Neupro is rotigotine. Each patch is designed to deliver a specific dose over 24 hours: the 1 mg/24h patch contains 2.25 mg of rotigotine, and the 3 mg/24h patch contains 6.75 mg of rotigotine. The total drug content exceeds the delivered dose because not all medication is released during the 24-hour wear period.
Understanding the composition of Neupro helps patients identify potential allergens and understand how the patch is constructed. The patch consists of three layers: a backing layer, a drug-containing adhesive matrix, and a protective release liner that is removed before application.
Active Ingredient
- Rotigotine – available in 1 mg/24h (5 cm² patch containing 2.25 mg) and 3 mg/24h (15 cm² patch containing 6.75 mg) strengths
Other Ingredients
- Poly(dimethylsiloxane, trimethylsilyl silicate) copolymer
- Povidone K90
- Sodium metabisulfite (E223) – may cause allergic reactions in sensitive individuals
- Ascorbyl palmitate (E304)
- DL-α-tocopherol (E307)
The backing layer consists of a siliconised, aluminised, colour-pigmented polyester film. The aluminium content is the reason the patch must be removed before MRI scans. The release liner is a transparent fluoropolymer-coated polyester film that is discarded before application.
Appearance and Pack Sizes
Neupro patches are thin, square-shaped with rounded corners, and have a beige-coloured backing printed with "Neupro" and the strength. They are available in cartons containing 7, 14, 28, 30, or 84 patches (the 84-pack being a multipack of 3 cartons of 28). Each patch is individually sealed in a sachet. Not all pack sizes may be available in your country.
Can You Drive While Using Neupro?
Neupro can cause significant drowsiness and sudden, unpredictable episodes of falling asleep. If this occurs, you must not drive or operate machinery. Isolated cases of patients falling asleep while driving have been reported, resulting in accidents.
The potential for Neupro to cause somnolence (excessive sleepiness) and sudden sleep onset is a serious safety concern that all patients must be aware of. These effects can occur without warning signs and have led to road traffic accidents in isolated cases.
Before driving or using any tools or machinery while taking Neupro, consider the following:
- Pay attention to how the medication affects you personally – the degree of drowsiness varies between individuals
- Be especially vigilant during the early weeks of treatment and after any dose increase
- Avoid driving or operating machinery if you feel drowsy at any point during treatment
- The combination of Neupro with alcohol, sedating medications, or sleep deprivation further increases the risk of sudden sleep
If you experience excessive drowsiness or sudden sleep episodes at any point during treatment, stop driving and contact your doctor immediately. Your dose may need to be adjusted, or alternative treatment options may be considered.
Frequently Asked Questions About Neupro
Neupro (rotigotine) is a transdermal patch used to treat Restless Legs Syndrome (RLS) in adults. It delivers rotigotine, a dopamine agonist, continuously through the skin over 24 hours to reduce the uncomfortable sensations and urge to move the legs associated with RLS. The continuous delivery system provides steady medication levels, which may help reduce symptom fluctuations throughout the day and night.
No. You must remove the Neupro patch before undergoing an MRI scan or cardioversion procedure. The patch contains aluminium in its backing layer, which can heat up in the magnetic field and cause skin burns at the application site. Remove the patch just before the procedure and apply a new patch afterwards. Always inform the medical team performing the procedure that you use Neupro patches.
The most common side effects (affecting more than 1 in 10 people) are headache, nausea, fatigue/weakness, and skin reactions at the application site such as redness and itching. These side effects are usually mild to moderate and tend to occur during the early weeks of treatment. Nausea often improves as your body adjusts to the medication. Rotating the patch application site daily helps reduce skin irritation.
No, you should never stop Neupro abruptly without medical supervision. Sudden discontinuation can trigger neuroleptic malignant syndrome (NMS), a rare but potentially life-threatening condition with symptoms including severe muscle rigidity, high fever, rapid heartbeat, unstable blood pressure, and confusion. Your doctor will taper the dose gradually, typically reducing by 1 mg every other day for RLS patients.
Yes, like all dopamine agonists, Neupro can cause impulse control disorders. These include pathological gambling, compulsive shopping, binge eating, and increased sexual drive. Patients often do not recognise these changes themselves, so it is important that family members and caregivers are aware of this risk and monitor for unusual behaviours. If any of these develop, contact your doctor promptly – the dose may need to be reduced or the medication changed.
Apply the patch to clean, dry, intact skin on the shoulders, upper arms, abdomen, flanks, thighs, or hips. Remove the old patch first, then open the sachet and peel off the release liner without touching the adhesive surface. Press the patch firmly onto the skin for at least 30 seconds with the palm of your hand. Change the patch at approximately the same time each day, rotating to a different application site. Do not cut the patch. Wash your hands after handling.
References
- European Medicines Agency (EMA). Neupro – Summary of Product Characteristics. Updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/neupro
- U.S. Food and Drug Administration (FDA). Neupro (rotigotine transdermal system) – Prescribing Information. Available at: accessdata.fda.gov
- Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria. Sleep Medicine. 2014;15(8):860-873. doi:10.1016/j.sleep.2014.03.025
- Trenkwalder C, Winkelmann J, Oertel W, et al. Rotigotine effects on RLS symptoms and periodic limb movements during sleep: a randomized clinical trial. Neurology. 2021;96(13):e1835-e1847.
- National Institute for Health and Care Excellence (NICE). Restless legs syndrome – Management. Clinical Knowledge Summaries. Updated 2024.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd edition. Geneva: WHO; 2023.
- Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation. Sleep Medicine. 2016;21:1-11.
- Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Medicine. 2010;11(9):848-856.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in neurology, clinical pharmacology, and internal medicine. All content follows international guidelines and the GRADE evidence framework.
All medical claims verified against EMA SmPC, FDA prescribing information, and peer-reviewed clinical studies. Evidence level: 1A (systematic reviews and RCTs).
Independent medical editorial content with no pharmaceutical company sponsorship. Following WHO, EMA, and NICE guidelines.